PGNewsroom



Six Ways We Contribute to STEM Education Within Our Community 

Published on

At PreventionGenetics, we have always believed in giving back to our community. This is especially true when we have the privilege to support local organizations interested in helping students and adults gain access to high-quality education.  “The chance to foster individuals’ interests in genetics and contribute to public engagement with STEM has been a positive experience for PreventionGenetics,” noted Dr. James Weber, Founder and CEO of PreventionGenetics. “Our company is dedicated to supporting education at all levels.” 

Online DNA Banking in a few easy steps

Published on

DNA Banking just got easier. Patients can now order and submit payment online in a few easy steps. Providers can also assist their patients with banking and receive confirmation when the process is complete.  No more worrying about lost or incomplete paperwork, or tracking down payments. The online ordering system collects all required information for DNA banking, including specimen kit selection. Depositors have the choice to receive either a blood or saliva kit. Other specimen types are also accepted for DNA banking, but kits are not provided (see acceptable specimen types for more details). Get started today.

Expanded testing options for PGxome and large PGxome-based tests

Published on

PreventionGenetics is excited to announce the addition of Patient Plus for PGxomeⓇ and large exome-based tests - Autism Spectrum Disorders and Intellectual Disability panel and Neonatal Crisis panel. Patient Plus involves sequencing and copy number variant (CNV) analysis of the patient, and then use of the parental specimens to perform targeted testing for the key sequence variants found in the patient. This approach permits detection of de novo variants and phasing of variants in recessive genes.

Rapid Exome-based Testing for Neonatal Crisis

Published on

PreventionGenetics’ Neonatal Crisis panel is a unique ~1,200 gene panel designed for critically ill neonatal and pediatric patients. The panel includes sequencing and copy number variation detection as well as an accelerated turnaround time. The panel has yielded ~17% clear positive results.